Results 221 to 230 of about 39,758 (253)

[Clopidogrel resistance].

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2009
Platelets play a critical role in pathogenesis of atherothrombotic diseases such as acute coronary syndromes and ischemic stroke. Clopidogrel, a thienopyridine derivative is an effective antiplatelet drug mostly used in combination with aspirin or as a single drug in aspirin intolerant patients.
Yeşim, Güray, Umit, Güray, Sule, Korkmaz   +2 more
openaire   +1 more source

Clopidogrel Resistance: Implications for Coronary Stenting

Current Pharmaceutical Design, 2006
Clopidogrel, in combination wih aspirin, is currently the drug of choice to prevent thrombosis after coronary stent implantation. Currently, clopidogrel is administered to the vast majority of patients without any assessment of platelet inhibition. Response variability and resistance, however, definitely occur to clopidogrel treatment. Preliminary data
Paul A, Gurbel, Wei C, Lau, Kevin P, Bliden, Udaya S, Tantry   +3 more
openaire   +2 more sources

Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?

The Journal of Clinical Pharmacology, 2009
Clopidogrel is important for the management of acute coronary syndromes and, along with aspirin, is recommended in the American College of Cardiology/American Heart Association guideline. It is also used along with aspirin, during the placement of coronary artery stents.
openaire   +2 more sources

Clopidogrel “resistance”: Pre- vs post-receptor determinants

Vascular Pharmacology, 2013
The clinical efficacy of the P2Y12 receptor antagonist clopidogrel as an agent to prevent thrombotic events predominantly reflects its anti-aggregatory effects. Stent thrombosis in particular is more likely to occur in patients in whom clopidogrel effect is limited.
Hurst N.L., Nooney V.B., Raman B., Chirkov Y.Y., De Caterina R., Horowitz J.D.   +5 more
openaire   +6 more sources

Adrenoreceptors, platelet reactivity and clopidogrel resistance

Thrombosis and Haemostasis, 2008
Thromb Haemost 2008; 100: 729–730 Platelet activation plays a central role in haemostasis and thrombosis. Antiplatelet therapy is considered to be the ‘cornerstone’in the prevention and treatment of thrombotic diseases such as coronary artery disease (CAD), stroke and peripheral arterial disease (PAD).
openaire   +2 more sources

Clopidogrel Response Variability, Resistance, or Both?

The American Journal of Cardiology, 2006
Dual antiplatelet therapy represents an important advance for patients with established cardiovascular disease. Variable platelet response and potential resistance to therapy have emerged with aspirin and clopidogrel. There is no clear and accepted definition of clopidogrel resistance, but patients with lower responses to clopidogrel are at risk for ...
openaire   +2 more sources

Clopidogrel resistance / Clopidogrel-Resistenz

LaboratoriumsMedizin, 2006
Tobias Geisler, Meinrad Gawaz
openaire   +1 more source

Evaluation of clopidogrel resistance

Thrombosis Research, 2005
Zakaria Ali, Almsherqi, Craig, McLachlan, Peter J, Mossop, Yuru, Deng   +3 more
openaire   +2 more sources

[Variable extent of platelet responsiveness to clopidogrel inhibition: "clopidogrel resistance"?].

Annales de cardiologie et d'angeiologie, 2005
During percutaneous coronary angioplasty, platelet inhibition by clopidogrel and aspirin has drastically decreased the risk of thrombotic occlusion of the stented vessels. However, despite the widespread use of these drugs, the incidence of acute or subacute stent thrombosis remains elevated, concerning 1 to 2% of the treated patients.
O, Morel, P, Ohlmann, L, Jesel, N, Morel, C, Ridard, A, Faure, L, Grunebaum, F, Toti, P, Bareiss   +8 more
openaire   +1 more source

[Clopidogrel resistance: myth or reality].

Kardiologiia, 2008
The efficacy of clopidogrel, as an established anti-platelet agent for the acute coronary syndrome treatment and for the thrombotic complications prevention after percutaneous coronary angioplasty and coronary artery stenting has been supported by the evidence of several major randomized clinical trials.
V L, Serebrianyĭ, A I, Malinin, L M, Makarov   +2 more
openaire   +1 more source